BioVie said it has completed the last patient evaluation visit in its Phase 2 SUNRISE-PD trial of bezisterim in early-stage Parkinson’s disease. Topline data are targeted for Q3 2026.
BioVie said it has completed the last patient evaluation visit in its Phase 2 SUNRISE-PD trial of bezisterim in early-stage Parkinson’s disease, marking a key milestone for the program ahead of topline results expected in the third quarter of 2026.
The company disclosed the update on May 18, 2026. Reuters-syndicated coverage repeated the announcement the same day.
SUNRISE-PD enrolled 60 patients, according to BioVie’s investor relations site. The company had previously said enrollment was completed in January 2026.
The latest update means the trial has moved past patient visits and into the next phase of data analysis. BioVie has not yet released the study results.
What comes next
BioVie said topline data are targeted for Q3 2026. Until then, the company has not disclosed additional trial-design details or safety findings beyond the completion update.
The announcement adds another step in BioVie’s Parkinson’s program after the company earlier highlighted the study in March 2026 and said the trial had opened with first-patient enrollment in April 2025.
Revision note
Initial automated publication.